16896005

Source:http://linkedlifedata.com/resource/pubmed/id/16896005

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0024305, umls-concept:C0030705, umls-concept:C0055598, umls-concept:C0282460, umls-concept:C0393022, umls-concept:C1413947
pubmed:issue	25
pubmed:dateCreated	2006-8-31
pubmed:abstractText	To evaluate the safety and efficacy of rituximab adjunction to the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/16896005-17308260, http://linkedlifedata.com/resource/pubmed/commentcorrection/16896005-17308261
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal..., http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Prednisone, http://linkedlifedata.com/resource/pubmed/chemical/Vincristine, http://linkedlifedata.com/resource/pubmed/chemical/rituximab
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	1527-7755
pubmed:author	pubmed-author:BillaudEricE, pubmed-author:BonnetFabriceF, pubmed-author:BouéFrançoisF, pubmed-author:CheretAntoineA, pubmed-author:CostagliolaDominiqueD, pubmed-author:GabarreJeanJ, pubmed-author:GisselbrechtChristianC, pubmed-author:LancarRemiR, pubmed-author:RaphaelMartineM, pubmed-author:ReynesJacquesJ
pubmed:issnType	Electronic
pubmed:day	1
pubmed:volume	24
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	4123-8
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:16896005-Adult, pubmed-meshheading:16896005-Antibodies, Monoclonal, pubmed-meshheading:16896005-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:16896005-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16896005-Cyclophosphamide, pubmed-meshheading:16896005-Doxorubicin, pubmed-meshheading:16896005-Feasibility Studies, pubmed-meshheading:16896005-Female, pubmed-meshheading:16896005-Hodgkin Disease, pubmed-meshheading:16896005-Humans, pubmed-meshheading:16896005-Lymphoma, AIDS-Related, pubmed-meshheading:16896005-Male, pubmed-meshheading:16896005-Middle Aged, pubmed-meshheading:16896005-Neoplasm Staging, pubmed-meshheading:16896005-Prednisone, pubmed-meshheading:16896005-Prognosis, pubmed-meshheading:16896005-Risk Factors, pubmed-meshheading:16896005-Survival Analysis, pubmed-meshheading:16896005-Treatment Outcome, pubmed-meshheading:16896005-Vincristine
pubmed:year	2006
pubmed:articleTitle	Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
pubmed:affiliation	Agence Nationale Recherche sur le Sida et les Hépatites, Paris, France. francois.boue@abc.aphp.fr
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II